Comparative diagnostic sensitivity of the substantia nigra transcranial sonography and salivary gland biopsy in patients with Parkinson’s disease

Abstract

Parkinson’s disease is a chronic neurodegenerative disease, the diagnosis of which remains challenging at the early stages, although clinical diagnostic criteria are developed. The diagnostic accuracy is only 58% for patients at early Parkinson’s disease stages. The sensitivity and specificity of transcranial sonography of the substantia nigra used for Parkinson’s disease verification is about 85% and 71%, respectively. It has been shown that the aggregates of α-synuclein in the nerve fibers in major salivary glands may be seen in Parkinson’s disease patients. The availability of the salivary glands for morphological study made it possible to investigate the approaches of the in vivo histological diagnosis of Parkinson’s disease based on the detection of α-synuclein aggregates in the nerve fibers innervating the glands.

Aim: To evaluate and compare the sensitivity of transcranial sonography of the substantia nigra and sublingual salivary gland biopsy.

Materials and methods: Six patients with clinically verified Parkinson’s disease were enrolled. Evaluation of the neurological state using special scales, transcranial sonography of the substantia nigra and sublingual salivary gland biopsy was performed.

Results: Mean age of patients was 59 [58; 60.7] years, mean disease duration period was 5 [3; 7.75] years and the mean Hoehn–Yahr stage was 2.25 [2; 2.5]. Hyperechogenicity of the substantia nigra was found in 3 of 6 patients and the substantia nigra sensitivity was shown to be 50%. Sublingual salivary gland biopsy was positive for α-synuclein in 6 of 6 patients and the sensitivity of method was shown to be 100%. No adverse events after biopsy were registered.

Conclusion: The sensitivity of sublingual salivary gland biopsy was higher than those of transcranial sonography of the substantia nigra, which indicates the prospect of using the biopsy method as a more sensitive diagnostic tool in Parkinson’s disease (1 table, bibliography: 19 refs)

Keywords

α-synuclein / biopsy of the salivary gland / diagnostics / neurodegenerative disease / Parkinson’s disease / peripheral nervous system / transcranial sonography of the substantia nigra

References

[1] Razdorskaya VV, Voskresenskaya ON, Yudina GK. Parkinson’s disease in Russia: prevalence and incidence. Saratov Journal of Medical Scientific Research. 2016;12(3):379–384. (In Russ.)

[2] Раздорская В.В., Воскресенская О.Н., Юдина Г.К. Болезнь Паркинсона в России: распространенность и заболеваемость // Саратовский научно-медицинский журнал. 2016. Т. 12, № 3. C. 379–384.

[3] Illarioshkin SN. Parkinson’s disease course and approaches to early diagnosis. In: Illarioshkin SN, Levin OS, eds. Parkinson’s disease and movement disorders. A guide for physicians based on the materials of the II National Congress. Moscow: Serebryanye niti Publisher; 2011: 41–47. (In Russ.)

[4] Иллариошкин С.Н. Течение болезни Паркинсона и подходы к ранней диагностике. В кн.: Болезнь Паркинсона и расстройства движений / под ред. С.Н. Иллариошкина, О.С. Левина. Руководство для врачей по материалам II Национального конгресса. М.: Серебряные нити, 2011. С. 41–47.

[5] Gopalakrishna A, Alexander SA. Understanding Parkinson disease: a complex and multifaceted illness. J Neurosci Nurs. 2015;47(6):320–326.

[6] Gopalakrishna A., Alexander S.A. Understanding Parkinson disease: a complex and multifaceted illness // J. Neurosci. Nurs. 2015. Vol. 47, No. 6. P. 320–326.

[7] Alekseeva NS, Illarioshkin SN, Ponomareva TA, Fedotova EYu, Ivanova-Smolenskaya IA. Smell disorders in Parkinson’s disease. Neurological Journal. 2012;17(1):10–14. (In Russ.)

[8] Алексеева Н.С., Иллариошкин С.Н., Пономарева Т.А., и др. Нарушения обоняния при болезни Паркинсона // Неврологический журнал. 2012. Т. 17, № 1. C. 10–14.

[9] Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11): 1641–1649. DOI: 10.1002/mds.22643

[10] Barone P., Antonini A., Colosimo C., et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease // Mov. Disord. 2009. Vol. 24, No. 11. P. 1641–1649. DOI: 10.1002/mds.22643

[11] Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neuroscience letters. 2006;396(1):67–72.

[12] Braak H., de Vos R.A., Bohl J., Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology // Neuroscience letters. 2006. Vol. 396, No. 1. P. 67–72.

[13] Salkov VN, Voronkov DV, Khacheva KK, et al. Clinical and morphological analysis of a case of Parkinson’s disease. Arkhiv Patologii. 2020;82(2):52–56. DOI: 10.17116/patol20208202152. (In Russ.)

[14] Сальков В.Н., Воронков Д.Н., Хачева К.К., и др. Клинико-морфологический анализ случая болезни Паркинсона // Архив патологии. 2020. Т. 82, № 2. С. 52–56. DOI: 10.17116/patol20208202152

[15] Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. DOI: 10.1002/mds.26424

[16] Postuma R.B., Berg D., Stern M., et al. MDS clinical diagnostic criteria for Parkinson’s disease // Mov. Disord. 2015. Vol. 30, No. 12. P. 1591–1601. DOI: 10.1002/mds.26424

[17] Beach TG, Adler CH. Importance of low diagnostic accuracy for early Parkinson’s disease. Mov Disord. 2018;33(10):1551–1554.

[18] Beach T.G., Adler C.H. Importance of low diagnostic accuracy for early Parkinson’s disease // Mov. Disord. 2018. Vol. 33, No. 10. P. 1551–1554.

[19] Mei YL, Yang J, Wu ZR, et al. Transcranial Sonography of the Substantia Nigra for the Differential Diagnosis of Parkinson’s Disease and Other Movement Disorders: A Meta-Analysis. Parkinsons Dis. 2021;2021:8891874. DOI: 10.1155/2021/8891874

[20] Mei Y.L., Yang J., Wu Z.R., et al. Transcranial Sonography of the Substantia Nigra for the Differential Diagnosis of Parkinson’s Disease and Other Movement Disorders: A Meta-Analysis // Parkinsons Dis. 2021. Vol. 2021. P. 8891874. DOI: 10.1155/2021/8891874

[21] Campo F, Carletti R, Fusconi M, et al. Alpha-synuclein in salivary gland as biomarker for Parkinson’s disease. Rev Neurosci. 2019;30(5):455–462. DOI: 10.1515/revneuro-2018-0064

[22] Campo F., Carletti R., Fusconi M., et al. Alpha-synuclein in salivary gland as biomarker for Parkinson’s disease // Rev. Neurosci. 2019. Vol. 30, No. 5. P. 455–462. DOI: 10.1515/revneuro-2018–0064

[23] Beach TG, Adler CH, Dugger BN, et al. Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol. 2013;72(2):130–136. DOI: 10.1097/NEN.0b013e3182805c72

[24] Beach T.G., Adler C.H., Dugger B.N., et al. Submandibular gland biopsy for the diagnosis of Parkinson disease // J. Neuropathol. Exp. Neurol. 2013. Vol. 72, No. 2. P. 130–136. DOI: 10.1097/NEN.0b013e3182805c72

[25] Folgoas E, Lebouvier T, Leclair-Visonneau L, et al. Diagnostic value of minor salivary glands biopsy for the detection of Lewy pathology. Neurosci Lett. 2013;551:62–64. DOI: 10.1016/j.neulet.2013.07.016

[26] Folgoas E., Lebouvier T., Leclair-Visonneau L., et al. Diagnostic value of minor salivary glands biopsy for the detection of Lewy pathology // Neurosci. Lett. 2013. Vol. 551. P. 62–64. DOI: 10.1016/j.neulet.2013.07.016

[27] Berquin K, Mahy P, Weynand B, Reychler H. Accessory or sublingual salivary gland biopsy to assess systemic disease: a comparative retrospective study. Eur Arch Otorhinolaryngol. 2006;263(3):233–236. DOI: 10.1007/s00405-005-0984-4

[28] Berquin K., Mahy P., Weynand B., Reychler H. Accessory or sublingual salivary gland biopsy to assess systemic disease: a comparative retrospective study // Eur. Arch. Otorhinolaryngol. 2006. Vol. 263, No. 3. P. 233–236. DOI: 10.1007/s00405-005-0984-4

[29] Sobolev VB, Khudoyerkov RM, Bogdanov RR, et al. Identification of Phosphorylated α-synuclein in Salivary Gland Biopsy Samples in Parkinson’s Disease. Nervous Diseases. 2018;(3):44–50. DOI: 10.24411/2071-5315-2018-12033 (In Russ.)

[30] Соболев В.Б., Худоерков Р.М., Богданов Р.Р., и др. Выявление фосфорилированного α-синуклеина в биопсийном материале слюнных желез при болезни Паркинсона // Нервные болезни. 2018. № 3. C. 44–50. DOI: 10.24411/2071-5315-2018-12033

[31] Visanji NP, Mollenhauer B, Beach TG, et al. The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson’s disease. Biomark Med. 2017;11(4):359–368. DOI: 10.2217/bmm-2016-0366

[32] Visanji N.P., Mollenhauer B., Beach T.G., et al. The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson’s disease // Biomark. Med. 2017. Vol. 11, No. 4. P. 359–368. DOI: 10.2217/bmm-2016-0366

[33] Martinez-Martin P, Rodríguez-Blázquez C, Mario Alvarez, et al. Parkinson’s disease severity levels and MDS-Unified Parkinson’s Disease Rating Scale. Parkinsonism Relat Disord. 2015;21(1):50–54. DOI: 10.1016/j.parkreldis.2014.10.026

[34] Martinez-Martin P., Rodríguez-Blázquez C., Mario Alvarez, et al. Parkinson’s disease severity levels and MDS-Unified Parkinson’s Disease Rating Scale // Parkinsonism Relat. Disord. 2015. Vol. 21, No. 1. P. 50–54. DOI: 10.1016/j.parkreldis.2014.10.026

[35] Jenkinson C, et al. The PDQ-8: development and validation of a short-form Parkinson’s disease questionnaire. Psychology and Health. 1997;12(6):805–814. DOI: 10.1080/08870449708406741

[36] Jenkinson C., Fitzpatrick R., Peto V., Greenhall R., Hyman N. The PDQ-8: development and validation of a short-form Parkinson’s disease questionnaire // Psychology and Health. 1997. Vol. 12, No. 6. P. 805–814. DOI: 10.1080/08870449708406741

[37] Hanna KK, Cronin-Golomb A. Impact of anxiety on quality of life in Parkinson’s disease. Parkinsons Dis. 2012;2012:640707. DOI: 10.1155/2012/640707

[38] Hanna K.K., Cronin-Golomb A. Impact of anxiety on quality of life in Parkinson’s disease // Parkinsons Dis. 2012. Vol. 2012. P. 640707. DOI: 10.1155/2012/640707

RIGHTS & PERMISSIONS

Khacheva K.K., Illarioshkin S.N., Karabanov A.V., Chechetkin A.O.